0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RENIN

RENIN

RENIN Molecule Information

Name:Renin
Target Synonym:REN;Angiotensinogenase;Renin
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:44
Lastest Research Phase:Approved

RENIN Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
REN-M5222 Mouse Mouse RENIN Protein, His Tag
REN-M5222-structure
REN-M5222-sds
REN-H5221 Human Human RENIN Protein, His Tag
REN-H5221-structure
REN-H5221-sds

RENIN Molecule Synonym Name

REN,FLJ10761,Renin,angiotensinogenase

RENIN Molecule Background

Renin is also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body's renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2. The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3' UTR. An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.

RENIN References

RENIN Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aliskiren Hemifumarate/Amlodipine Besylate SPA-100 Approved Novartis TEKAMLO fda NOVARTIS 2010-08-26 Hypertension Details
Aliskiren Hemifumarate/Hydrochlorothiazide Approved Novartis TEKTURNA HCT fda NODEN PHARMA 2008-01-18 Hypertension Details
Aliskiren Hemifumarate CGP-60536; CGP-60536B; SPP-100A; SPP-100; SPP-100B,CGP60536B,SPP 100,SPP100A,CGP 60536,CGP60536,CGP 60536B,SPP100,SPP 100A Approved Novartis, Noden Pharma, Lee's Pharm TEKTURNA fda Hypertension NODEN PHARMA 2007-03-05 Hypertension, Primary hypertension Details

RENIN Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SQ-34017 SQ-34017 Preclinical Bristol-Myers Squibb Hypertension Details
L-363564 L-363564 Phase Not Specified Merck Sharp & Dohme Hypertension Details
SQ-30774 SQ-30774 Preclinical Bristol-Myers Squibb Hypertension Details
Ciprokiren RO-449375,RO 449375 Preclinical Roche Hypertension, Heart failure Details
Terlakiren CP-80794,CP 80794,CP80794 Phase Ⅱ Pfizer Hypertension Details
ES-6864 ES-6864 Phase Ⅰ Daiichi Sankyo Hypertension Details
IONIS-AGT-LRx IONISAGTLRx; ISIS-757456; ISISAGTLRx Phase Ⅱ Ionis Pharmaceuticals Hypertension Details
FK-906 FK-906; FR-115906 Phase Ⅱ Astellas Hypertension Details
SR-43845 SR-43845 Phase Ⅱ Sanofi Hypertension Details
SPP-676 SPP-676 Phase Ⅰ Novartis Hypertension Details
YM-21095 YM-21095,YM 21095,YM21095 Preclinical Astellas Hypertension Details
R-Pep-27 R-Pep-27 Phase Ⅰ National Institutes of Health Hypertension Details
ES-8891 ES-8891; RS-8891 Phase Ⅰ Daiichi Sankyo Hypertension Details
Ro-AAA Ro-AAA Phase Not Specified Roche Hypertension Details
A-74273 A-74273 Phase Ⅰ Abbott Hypertension Details
DSP-9599 DSP-9599 Phase Ⅰ Sumitomo Dainippon Hypertension Details
ICI-219623 ICI-219623 Preclinical AstraZeneca Hypertension Details
Imarikiren hydrochloride SCO-272; TAK-272 Phase Ⅱ Takeda Hypertension, Diabetic nephropathy Details
Remikiren mesilate RO-425892; RO-425892/001 Phase Ⅱ Roche Hypertension, Heart failure Details
SC-32796 SC-32796 Preclinical Pfizer Kidney disorders, Hypertension Details
Zankiren A-72517; Abbott-72 517 Phase Ⅱ Abbott Hypertension Details
H-142 H-142 Phase Ⅱ AstraZeneca Hypertension, Heart failure Details
ACT-178882 ACT-178882; MK-1597 Phase Ⅰ Actelion, Merck Sharp & Dohme Hypertension Details
VTP-27999 VTP-27999,VTP27999 Phase Ⅰ Vitae Chronic kidney disease Details
Ditekiren U-71038 Phase Ⅱ Pfizer Hypertension, Heart failure Details
CGP-38560A CGP-38560A Phase Ⅰ Novartis Hypertension Details
ACT-077825 ACT-077825; MK-8141; Act-AAA ,ACT077825,MK8141 Phase Ⅱ Actelion, Merck Sharp & Dohme Hypertension Details
SPP-1148 SPP-1148 Phase Ⅰ Novartis Hypertension Details
CL-331049 CL-331049 Preclinical Pfizer Hypertension Details
PD-132002 PD-132002,PD 132002,PD132002 Preclinical Pfizer Hypertension Details
A-65317 A-65317,A 65317,A65317 Preclinical Abbott Hypertension Details
ES-305 ES-305,ES 305,ES305 Preclinical Daiichi Sankyo Hypertension Details
Enalkiren A-64662; Abbott-64662 Phase Ⅱ Abbott Kidney disorders, Hypertension, Glaucoma Details
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide Withdrawn Novartis Hypertension Details
WAY-121604 WAY-121604 Preclinical Pfizer Hypertension Details
L-157119 L-157119 Phase Not Specified Merck Sharp & Dohme Hypertension Details
A-68064 A-68064 Preclinical Abbott Hypertension Details
Aliskiren Hemifumarate/Valsartan Withdrawn Novartis Hypertension Details
SPP-635 SPP-635; SPP-630 Phase Ⅱ Novartis Hypertension Details
SQ-31844 SQ-31844 Preclinical Bristol-Myers Squibb Hypertension Details
SP-20104 (Sarfez Pharmaceuticals) SP-20104 Phase Ⅱ 1 A Pharma GmbH Focal segmental glomerulosclerosis Details
A-67449 A-67449 Phase Not Specified Abbott Hypertension Details
GR-70982 GR-70982 Preclinical GlaxoSmithKline Hypertension Details
ES-1005 ES-1005 Preclinical Daiichi Sankyo Hypertension Details

This web search service is supported by Google Inc.

totop